DE102010012232A1 - New imidazole useful in pharmaceutical preparation e.g. for prevention or treatment of cancer diseases, pathological effects of alcohol misuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases - Google Patents

New imidazole useful in pharmaceutical preparation e.g. for prevention or treatment of cancer diseases, pathological effects of alcohol misuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases Download PDF

Info

Publication number
DE102010012232A1
DE102010012232A1 DE102010012232A DE102010012232A DE102010012232A1 DE 102010012232 A1 DE102010012232 A1 DE 102010012232A1 DE 102010012232 A DE102010012232 A DE 102010012232A DE 102010012232 A DE102010012232 A DE 102010012232A DE 102010012232 A1 DE102010012232 A1 DE 102010012232A1
Authority
DE
Germany
Prior art keywords
alkyl
pharmaceutically acceptable
halogen
cyclopropyl
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102010012232A
Other languages
German (de)
Inventor
Dr. Diesinger Torsten
Dr. Haehner Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ACROVIS BIOSTRUCTURES GmbH
Original Assignee
ACROVIS BIOSTRUCTURES GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ACROVIS BIOSTRUCTURES GmbH filed Critical ACROVIS BIOSTRUCTURES GmbH
Priority to DE102010012232A priority Critical patent/DE102010012232A1/en
Publication of DE102010012232A1 publication Critical patent/DE102010012232A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Imidazole (I), is new. Imidazole of formula (I) and its salt, are new. n : 7-14; R1 : H, halo, 1-6C alkyl, 3-8C cycloalkyl or aryl; R2 : H, halo, 1-6C alkyl or 3-8C cycloalkyl; and R3 : H, halo, 1-6C alkyl, 1-6C alkyl-carbamoyl, aryl-carbamoyl or aryl-1-2C-alkyl-carbamoyl, where at least one of R1, R2 and R3 is not H. [Image] ACTIVITY : Cytostatic; Nephrotropic; Antiinflammatory; Hepatotropic; Virucide; Antidiabetic; Antidote; Antilipemic; Vasotropic; Antialcoholic. No biological data given. MECHANISM OF ACTION : None given.

Description

Die Erfindung betrifft Imidazole sowie pharmazeutisch akzeptable Salze davon, ihre Herstellung sowie pharmazeutische Präparate enthaltend diese Imidazole oder pharmazeutisch akzeptable Salze davon.The invention relates to imidazoles and pharmaceutically acceptable salts thereof, their preparation and pharmaceutical preparations containing these imidazoles or pharmaceutically acceptable salts thereof.

Aus WO 2007/124734 A2 (Mueller-Enoch und Haehner) ist u. a. eine antineoplastische Wirkung und Cytotoxizität von 12-Imidazolyl-1-dodecanol bekannt, das auch die Bewegungsaktivität von HepG2-Zellen hemmt.Out WO 2007/124734 A2 (Mueller-Enoch and Haehner), inter alia, an antineoplastic action and cytotoxicity of 12-imidazolyl-1-dodecanol is known, which also inhibits the movement activity of HepG2 cells.

Aus WO 2005/105079 A2 (Bolton et al., Warner-Lambert) sind substituierte Imidazole bekannt, als potente Inhibitoren der Cholesterol-Biosynthese.Out WO 2005/105079 A2 (Bolton et al., Warner-Lambert), substituted imidazoles are known to be potent inhibitors of cholesterol biosynthesis.

Aus GB 2.016.452 A (Iizuka et al., Ono Pharmaceutical) sind substituierte Imidazole bekannt, als Inhibitoren der Thromboxan-Synthetase.Out GB 2,016,452 A (Iizuka et al., Ono Pharmaceutical), substituted imidazoles are known as inhibitors of thromboxane synthetase.

Ping Lu et al., Archives of Biochemistry and Biophysics 1997, 1–7 , berichten über eine Reihenuntersuchung mit substituierten Imidazolen als Inhibitoren der Fettsäure-ώ-Hydroxylierung. Ping Lu et al., Archives of Biochemistry and Biophysics 1997, 1-7 , report on a screening with substituted imidazoles as inhibitors of fatty acid ώ-hydroxylation.

Davon ausgehend war es Aufgabe der vorliegenden Erfindung, in besonderer Weise substituierte Imidazole zur Verfügung zu stellen, mit denen sich ein therapeutischer Fortschritt erzielen lässt, insbesondere hinsichtlich Vorbeugung oder Behandlung von Krebserkrankungen, pathologischen Folgen des Alkoholmissbrauchs, viraler Hepatitis, Steato-Hepatitis, akuter und chronischer Pankreatitis, toxischer Nierenerkrankungen, hepatischer Insulinresistenz bei Diabetes mellitus, Leberschäden bei Morbus Wilson und Siderosen, Ischämie-Reperfusionsschäden, als Antidote gegen Umweltgifte und Medikamentenintoxikation, zur Verlängerung der Verweildauer von pharmazeutischen Medikamenten im Organismus, zur Bekämpfung toxischer Nebenwirkungen bei der Verabreichung von Chemotherapeutica, zur Vorbeugung oder Behandlung von Hyperlipidämien/Dyslipidämien, oder zur Vermeidung von Reperfusionsschäden bei transplantierten Organen, insbesondere vor und während der Lagerung, sowie kurz vor dem Implantieren in den Empfängerorganismus.On this basis, it was an object of the present invention to provide substituted imidazoles in a special way, with which a therapeutic progress can be achieved, in particular with regard to the prevention or treatment of cancers, pathological consequences of alcohol abuse, viral hepatitis, steato-hepatitis, acute and chronic pancreatitis, toxic kidney disease, hepatic insulin resistance in diabetes mellitus, liver damage in Wilson's disease and siderosis, ischemia-reperfusion injury, as an antidote to environmental toxins and drug intoxication, to prolong the residence time of pharmaceutical drugs in the organism, to combat toxic side effects when administering chemotherapeutic, for the prevention or treatment of hyperlipidemias / dyslipidemias, or for the prevention of reperfusion damage in transplanted organs, in particular before and during storage, as well as shortly before implantation in the recipient organism.

Dementsprechend betrifft die vorliegende Erfindung Imidazole der Formel (1)

Figure 00020001
worin n 7–14 bedeutet, R1 H, Halogen, C1-C6-Alkyl, C3-C8-Cycloalkyl oder Aryl bedeutet, R2 H, Halogen, C1-C6-Alkyl oder C3-C8-Cycloalkyl bedeutet, und R3 H, Halogen, C1-C6-Alkyl, C1-C6-Alkyl-carbamoyl, Aryl-carbamoyl oder Aryl-C1-C2-alkyl-carbamoyl bedeutet, wobei mindestens eines von R1, R2 und R3 ungleich H ist, sowie pharmazeutisch akzeptable Salze davon.Accordingly, the present invention relates to imidazoles of the formula (1)
Figure 00020001
wherein n is 7-14, R 1 is H, halogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl or aryl, R 2 is H, halogen, C 1 -C 6 alkyl or C 3 -C 8 -cycloalkyl, and R 3 is H, halogen, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl-carbamoyl, aryl-carbamoyl or aryl-C 1 -C 2 -alkyl-carbamoyl, where at least one R 1 , R 2 and R 3 are not H, and pharmaceutically acceptable salts thereof.

Halogen steht darin insbesondere für Chlor, Fluor oder Pseudohalogen, wie Cloromethyl, Fluoromethyl, Trifluoromethyl oder 1,1,1-Trifluoroethyl.Halogen is especially chlorine, fluorine or pseudohalogen, such as chloromethyl, fluoromethyl, trifluoromethyl or 1,1,1-trifluoroethyl.

C1-C6-Alkyl steht darin insbesondere für Methyl, Ethyl, n-Propyl, i-Propyl, n-Butyl, sec-Butyl oder tert-Butyl.C 1 -C 6 -alkyl is especially methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl or tert-butyl.

C3-C8-Cycloalkyl steht darin insbesondere für Cyclopropyl.C 3 -C 8 -cycloalkyl is in particular cyclopropyl.

Aryl steht darin insbesondere für Phenyl oder Halogen-substituiertes Phenyl, wie 4-Fluoro-phenyl oder 4-Chloro-phenyl.Aryl is in particular phenyl or halogen-substituted phenyl, such as 4-fluoro-phenyl or 4-chloro-phenyl.

C1-C6-Alkyl-carbamoyl steht darin insbesondere für Ethyl-carbamoyl, Aryl-carbamoyl für Phenyl-carbamoyl, und Aryl-C1-C2-alkyl-carbamoyl für Benzyl-carbamoyl oder Phenyl-ethyl-carbamoyl.In this formula, C 1 -C 6 -alkyl carbamoyl is in particular ethylcarbamoyl, arylcarbamoyl is phenylcarbamoyl, and arylC 1 -C 2 -alkylcarbamoyl is benzylcarbamoyl or phenylethylcarbamoyl.

Bevorzugt sind dabei solche Imidazole der Formel (1), worin n 9–12 bedeutet, R1 H, Halogen, C1-C3-Alkyl, Cyclopropyl, Phenyl oder Halogen-phenyl bedeutet, R2 H, Halogen, C1-C3-Alkyl oder Cyclopropyl bedeutet, und R3 H, Halogen, C1-C3-Alkyl, Phenyl-carbamoyl oder Benzyl-carbamoyl bedeutet, wobei mindestens eines von R1, R2 und R3 ungleich H ist.Preferred imidazoles of the formula (1) are those in which n is 9-12, R 1 is H, halogen, C 1 -C 3 -alkyl, cyclopropyl, phenyl or halophenyl, R 2 is H, halogen, C 1 - C 3 alkyl or cyclopropyl and R 3 is H, halogen, C 1 -C 3 alkyl, phenyl carbamoyl or benzyl carbamoyl, wherein at least one of R 1 , R 2 and R 3 is other than H.

Besonders bevorzugt sind dabei solche Imidazole der Formel (1), worin n 11 bedeutet, R1 H, Halogen, C1-C3-Alkyl, Cyclopropyl, Phenyl oder Halogen-phenyl bedeutet, R2 H, Halogen, C1-C3-Alkyl oder Cyclopropyl bedeutet, und R3 H, Halogen, C1-C3-Alkyl, Phenyl-carbamoyl oder Benzyl-carbamoyl bedeutet, wobei mindestens eines von R1, R2 und R3 ungleich H ist.Particular preference is given here to those imidazoles of the formula (1) in which n is 11, R 1 is H, halogen, C 1 -C 3 -alkyl, cyclopropyl, phenyl or halophenyl, R 2 is H, halogen, C 1 -C 3 alkyl or cyclopropyl, and R 3 is H, halogen, C 1 -C 3 alkyl, phenyl carbamoyl or benzyl carbamoyl, wherein at least one of R 1 , R 2 and R 3 is other than H.

Ganz besonders bevorzugt sind dabei solche Imidazole der Formel (1), worin n 11 bedeutet, R1 H, Methyl, i-Propyl, Cyclopropyl, Phenyl oder 4-Fluoro-phenyl bedeutet, R2 H, Methyl, i-Propyl, oder Cyclopropyl bedeutet, und R3 H oder Benzyl-carbamoyl bedeutet, wobei mindestens eines von R1, R2 und R3 ungleich H ist.Very particular preference is given to those imidazoles of the formula (1) in which n is 11, R 1 is H, methyl, isopropyl, cyclopropyl, phenyl or 4-fluorophenyl, R 2 is H, methyl, isopropyl, or Cyclopropyl, and R 3 is H or benzylcarbamoyl, wherein at least one of R 1 , R 2 and R 3 is other than H.

Bevorzugte Beispiele für erfindungsgemäße Imidazole der Formel (1) sind folgende:
n = 11, R1 = Methyl, R2 und R3 = H; nämlich:
12-(2-Methyl-imidazolyl)-n-dodecanol-(1).
n = 11, R1 = i-Propyl, und R2 und R3 = H; nämlich:
12-(2-i-Propyl-imidazolyl)-n-dodecanol-(1).
n = 11, R1 = Cyclopropyl, R2 und R3 = H; nämlich:
12-(2-Cyclopropyl-imidazolyl)-n-dodecanol-(1).
n = 11, R1 = 4-Fluoro-phenyl, R2 und R3 = H; nämlich:
12-(2-(4-Fluoro-phenyl)-imidazolyl))-n-dodecanol-(1).
n = 11, R1 und R2 = H, R3 = Benzyl-carbamoyl; nämlich:
12-(4-Benzyl-carbamoyl-imidazolyl)-n-dodecanol-(1).Preferred examples of imidazoles of the formula (1) according to the invention are the following:
n = 11, R 1 = methyl, R 2 and R 3 = H; namely:
12- (2-methyl-imidazolyl) n-dodecanol (1).
n = 11, R 1 = i-propyl, and R 2 and R 3 = H; namely:
12- (2-i-propyl-imidazolyl) n-dodecanol (1).
n = 11, R 1 = cyclopropyl, R 2 and R 3 = H; namely:
12- (2-cyclopropyl-imidazolyl) n-dodecanol (1).
n = 11, R 1 = 4-fluorophenyl, R 2 and R 3 = H; namely:
12- (2- (4-Fluoro-phenyl) -imidazolyl)) - n-dodecanol (1).
n = 11, R 1 and R 2 = H, R 3 = benzylcarbamoyl; namely:
12- (4-benzyl-carbamoyl-imidazolyl) n-dodecanol (1).

Die vorliegende Erfindung betrifft auch pharmazeutische Präparate enthaltend ein derartiges Imidazol, oder ein pharmazeutisch akzeptables Salze davon.The present invention also relates to pharmaceutical preparations containing such an imidazole, or a pharmaceutically acceptable salt thereof.

Solche Präparate sind insbesondere geeignet zur Vorbeugung oder Behandlung von Krebserkrankungen, pathologischen Folgen des Alkoholmissbrauchs, viraler Hepatitis, Steato-Hepatitis, akuter und chronischer Pankreatitis, toxischer Nierenerkrankungen, hepatischer Insulinresistenz bei Diabetes mellitus, Leberschäden bei Morbus Wilson und Siderosen, Ischämie-Reperfusionsschäden, als Antidote gegen Umweltgifte und Medikamentenintoxikation, zur Verlängerung der Verweildauer von pharmazeutischen Medikamenten im Organismus, zur Bekämpfung toxischer Nebenwirkungen bei der Verabreichung von Chemotherapeutica, zur Vorbeugung oder Behandlung von Hyperlipidämien/Dyslipidämien, oder zur Vermeidung von Reperfusionsschäden bei transplantierten Organen, insbesondere vor und während der Lagerung, sowie kurz vor dem Implantieren in den Empfängerorganismus.Such preparations are particularly useful for the prevention or treatment of cancers, pathological effects of alcohol abuse, viral hepatitis, steato-hepatitis, acute and chronic pancreatitis, toxic kidney disease, hepatic insulin resistance in diabetes mellitus, liver damage in Wilson's disease and siderosis, ischemia-reperfusion injury Antidotes against environmental toxins and drug intoxication, for prolonging the residence time of pharmaceutical drugs in the organism, for controlling toxic side effects when administering chemotherapeutics, for the prevention or treatment of hyperlipidemias / dyslipidemias, or for preventing reperfusion damage to transplanted organs, in particular before and during storage , as well as just before implantation in the recipient organism.

Die erfindungsgemäßen Imidazole können nach an sich bekannten Verfahren hergestellt werden, insbesondere nach Verfahren, wie sie in WO 2007/124734 A2 , WO 2005/105079 A2 und GB 2.016.452 A beschrieben sind. Sie können in geeigneter Weise mit weiteren pharmazeutischen Wirkstoffen zusammen verwendet werden.The imidazoles according to the invention can be prepared by processes known per se, in particular by processes as described in US Pat WO 2007/124734 A2 . WO 2005/105079 A2 and GB 2,016,452 A are described. They may be suitably used together with other pharmaceutical agents.

Die erfindungsgemäßen pharmazeutischen Präparate können nach an sich bekannten Verfahren hergestellt werden, insbesondere nach Verfahren, wie sie in WO 2007/124734 A2 , WO 2005/105079 A2 und GB 2.016.452 A beschrieben sind. Solche Präparate können in geeigneter Weise weitere pharmazeutische Wirkstoffe enthalten.The pharmaceutical preparations according to the invention can be prepared by processes known per se, in particular by processes as described in US Pat WO 2007/124734 A2 . WO 2005/105079 A2 and GB 2,016,452 A are described. Such preparations may suitably contain other pharmaceutically active substances.

Geeignete Testmodelle für erfindungsgemäße Imidazole und pharmazeutische Präparate sind u. a. in WO 2007/124734 A2 beschrieben.Suitable test models for imidazoles and pharmaceutical preparations according to the invention are, inter alia, in WO 2007/124734 A2 described.

ZITATE ENTHALTEN IN DER BESCHREIBUNG QUOTES INCLUDE IN THE DESCRIPTION

Diese Liste der vom Anmelder aufgeführten Dokumente wurde automatisiert erzeugt und ist ausschließlich zur besseren Information des Lesers aufgenommen. Die Liste ist nicht Bestandteil der deutschen Patent- bzw. Gebrauchsmusteranmeldung. Das DPMA übernimmt keinerlei Haftung für etwaige Fehler oder Auslassungen.This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.

Zitierte PatentliteraturCited patent literature

  • WO 2007/124734 A2 [0002, 0019, 0020, 0021] WO 2007/124734 A2 [0002, 0019, 0020, 0021]
  • WO 2005/105079 A2 [0003, 0019, 0020] WO 2005/105079 A2 [0003, 0019, 0020]
  • GB 2016452 A [0004, 0019, 0020] GB 2016452 A [0004, 0019, 0020]

Zitierte Nicht-PatentliteraturCited non-patent literature

  • Ping Lu et al., Archives of Biochemistry and Biophysics 1997, 1–7 [0005] Ping Lu et al., Archives of Biochemistry and Biophysics 1997, 1-7 [0005]

Claims (11)

Imidazole der Formel (1)
Figure 00050001
worin n 7–14 bedeutet, R1 H, Halogen, C1-C6-Alkyl, C3-C8-Cycloalkyl oder Aryl bedeutet, R2 H, Halogen, C1-C6-Alkyl oder C3-C8-Cycloalkyl bedeutet, und R3 H, Halogen, C1-C6-Alkyl, C1-C6-Alkyl-carbamoyl, Aryl-carbamoyl oder Aryl-C1-C2-alkyl-carbamoyl bedeutet, wobei mindestens eines von R1, R2 und R3 ungleich H ist, sowie pharmazeutisch akzeptable Salze davon.Imidazoles of the formula (1)
Figure 00050001
wherein n is 7-14, R 1 is H, halogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl or aryl, R 2 is H, halogen, C 1 -C 6 alkyl or C 3 -C 8 -cycloalkyl, and R 3 is H, halogen, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl-carbamoyl, aryl-carbamoyl or aryl-C 1 -C 2 -alkyl-carbamoyl, where at least one R 1 , R 2 and R 3 are not H, and pharmaceutically acceptable salts thereof. Imidazole nach Anspruch 1, wobei n 9–12 bedeutet, R1 H, Halogen, C1-C3-Alkyl, Cyclopropyl, Phenyl oder Halogen-phenyl bedeutet, R2 H, Halogen, C1-C3-Alkyl oder Cyclopropyl bedeutet, und R3 H, Halogen, C1-C3-Alkyl, Phenyl-carbamoyl oder Benzyl-carbamoyl bedeutet, wobei mindestens eines von R1, R2 und R3 ungleich H ist, sowie pharmazeutisch akzeptable Salze davon.Imidazoles according to claim 1, wherein n is 9-12, R 1 is H, halogen, C 1 -C 3 -alkyl, cyclopropyl, phenyl or halo-phenyl, R 2 is H, halogen, C 1 -C 3 -alkyl or cyclopropyl and R 3 is H, halogen, C 1 -C 3 alkyl, phenylcarbamoyl or benzylcarbamoyl, wherein at least one of R 1 , R 2 and R 3 is other than H, and pharmaceutically acceptable salts thereof. Imidazole nach Anspruch 1, wobei n 11 bedeutet, R1 H, Halogen, C1-C3-Alkyl, Cyclopropyl, Phenyl oder Halogen-phenyl bedeutet, R2 H, Halogen, C1-C3-Alkyl oder Cyclopropyl bedeutet, und R3 H, Halogen, C1-C3-Alkyl, Phenyl-carbamoyl oder Benzyl-carbamoyl bedeutet, wobei mindestens eines von R1, R2 und R3 ungleich H ist, sowie pharmazeutisch akzeptable Salze davon.Imidazoles according to claim 1, wherein n is 11, R 1 is H, halogen, C 1 -C 3 -alkyl, cyclopropyl, phenyl or halophenyl, R 2 is H, halogen, C 1 -C 3 -alkyl or cyclopropyl, and R 3 is H, halo, C 1 -C 3 alkyl, phenyl carbamoyl or benzyl carbamoyl, wherein at least one of R 1 , R 2 and R 3 is other than H, and pharmaceutically acceptable salts thereof. Imidazole nach Anspruch 1, wobei n 11 bedeutet, R1 H, Methyl, i-Propyl, Cyclopropyl, Phenyl oder 4-Fluoro-phenyl bedeutet, R2 H, Methyl, i-Propyl, oder Cyclopropyl bedeutet, und R3 H oder Benzyl-carbamoyl bedeutet, wobei mindestens eines von R1, R2 und R3 ungleich H ist, sowie pharmazeutisch akzeptable Salze davon.Imidazoles according to claim 1, wherein n is 11, R 1 is H, methyl, i-propyl, cyclopropyl, phenyl or 4-fluorophenyl, R 2 is H, methyl, i-propyl, or cyclopropyl, and R 3 is H or Benzyl carbamoyl, wherein at least one of R 1 , R 2 and R 3 is other than H, and pharmaceutically acceptable salts thereof. Imidazole nach Anspruch 1, wobei n 11 bedeutet, R1 Methyl bedeutet, und R2 und R3 H bedeutet, nämlich 12-(2-Methyl-imidazolyl)-n-dodecanol-(1), sowie pharmazeutisch akzeptable Salze davon.Imidazoles according to claim 1, wherein n is 11, R 1 is methyl, and R 2 and R 3 are H, namely 12- (2-methylimidazolyl) -n-dodecanol- (1), and pharmaceutically acceptable salts thereof. Imidazole nach Anspruch 1, wobei n 11 bedeutet, R1 i-Propyl bedeutet, und R2 und R3 H bedeutet, nämlich 12-(2-i-Propyl-imidazolyl)-n-dodecanol-(1), sowie pharmazeutisch akzeptable Salze davon.Imidazoles according to claim 1, wherein n is 11, R 1 is i-propyl, and R 2 and R 3 are H, namely 12- (2-i-propyl-imidazolyl) -n-dodecanol- (1), as well as pharmaceutically acceptable Salts thereof. Imidazole nach Anspruch 1, wobei n 11 bedeutet, R1 Cyclopropyl und R2 und R3 H bedeutet, nämlich 12-(2-Cyclopropyl-imidazolyl)-n-dodecanol-(1), sowie pharmazeutisch akzeptable Salze davon.Imidazoles according to claim 1, wherein n is 11, R 1 is cyclopropyl and R 2 and R 3 are H, namely 12- (2-cyclopropyl-imidazolyl) -n-dodecanol- (1), as well as pharmaceutically acceptable salts thereof. Imidazole nach Anspruch 1, wobei n 11 bedeutet, R1 4-Fluoro-phenyl und R2 und R3 H bedeutet, nämlich 12-(2-(4-Fluoro-phenyl)-imidazolyl))-n-dodecanol-(1), sowie pharmazeutisch akzeptable Salze davon.Imidazoles according to claim 1, wherein n is 11, R 1 is 4-fluorophenyl and R 2 and R 3 are H, namely 12- (2- (4-fluorophenyl) -imidazolyl)) - n-dodecanol- (1 ), as well as pharmaceutically acceptable salts thereof. Imidazole nach Anspruch 1, wobei n 11 bedeutet, R1 und R2 H und R3 Benzyl-carbamoyl bedeutet, nämlich 12-(4-Benzyl-carbamoyl-imidazolyl)-n-dodecanol-(1), sowie pharmazeutisch akzeptable Salze davon.Imidazoles according to claim 1, wherein n is 11, R 1 and R 2 are H and R 3 is benzylcarbamoyl, namely 12- (4-benzyl-carbamoyl-imidazolyl) -n-dodecanol- (1), as well as pharmaceutically acceptable salts thereof , Pharmazeutisches Präparat enthaltend ein Imidazol nach einem der Ansprüche 1–9, oder ein pharmazeutisch akzeptables Salze davon.A pharmaceutical preparation containing an imidazole according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof. Pharmazeutisches Präparat enthaltend ein Imidazol nach einem der Ansprüche 1–9, oder ein pharmazeutisch akzeptables Salze davon, zur Vorbeugung oder Behandlung von Krebserkrankungen, pathologischen Folgen des Alkoholmissbrauchs, viraler Hepatitis, Steato-Hepatitis, akuter und chronischer Pankreatitis, toxischer Nierenerkrankungen, hepatischer Insulinresistenz bei Diabetes mellitus, Leberschäden bei Morbus Wilson und Siderosen, Ischämie-Reperfusionsschäden, als Antidote gegen Umweltgifte und Medikamentenintoxikation, zur Verlängerung der Verweildauer von pharmazeutischen Medikamenten im Organismus, zur Bekämpfung toxischer Nebenwirkungen bei der Verabreichung von Chemotherapeutica, zur Vorbeugung oder Behandlung von Hyperlipidämien/Dyslipidämien, oder zur Vermeidung von Reperfusionsschäden bei transplantierten Organen, insbesondere vor und während der Lagerung, sowie kurz vor dem Implantieren in den Empfängerorganismus.A pharmaceutical preparation containing an imidazole according to any of claims 1-9, or a pharmaceutically acceptable salt thereof, for the prevention or treatment of cancers, pathological effects of alcohol abuse, viral hepatitis, steato-hepatitis, acute and chronic pancreatitis, toxic kidney disease, hepatic insulin resistance Diabetes mellitus, liver damage in Wilson's disease and siderosis, ischemia-reperfusion damage, as antidotes to environmental toxins and drug intoxication, to prolong the residence time of pharmaceutical drugs in the organism, to combat toxic side effects when administering chemotherapeutics, for the prevention or treatment of hyperlipidemias / dyslipidemias, or to prevent reperfusion damage transplanted organs, especially before and during storage, as well as shortly before implantation in the recipient organism.
DE102010012232A 2010-03-19 2010-03-19 New imidazole useful in pharmaceutical preparation e.g. for prevention or treatment of cancer diseases, pathological effects of alcohol misuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases Withdrawn DE102010012232A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE102010012232A DE102010012232A1 (en) 2010-03-19 2010-03-19 New imidazole useful in pharmaceutical preparation e.g. for prevention or treatment of cancer diseases, pathological effects of alcohol misuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010012232A DE102010012232A1 (en) 2010-03-19 2010-03-19 New imidazole useful in pharmaceutical preparation e.g. for prevention or treatment of cancer diseases, pathological effects of alcohol misuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases

Publications (1)

Publication Number Publication Date
DE102010012232A1 true DE102010012232A1 (en) 2011-09-22

Family

ID=44585405

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102010012232A Withdrawn DE102010012232A1 (en) 2010-03-19 2010-03-19 New imidazole useful in pharmaceutical preparation e.g. for prevention or treatment of cancer diseases, pathological effects of alcohol misuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases

Country Status (1)

Country Link
DE (1) DE102010012232A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016452A (en) 1978-02-18 1979-09-26 Kissei Pharmaceutical Imidazole compounds
WO2005105079A2 (en) 2004-04-16 2005-11-10 Warner-Lambert Company Llc Novel imidazoles
WO2007124734A2 (en) 2006-04-28 2007-11-08 Dieter Mueller-Enoch Compounds a-r-x for the manufacture of pharmaceutical preparations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016452A (en) 1978-02-18 1979-09-26 Kissei Pharmaceutical Imidazole compounds
WO2005105079A2 (en) 2004-04-16 2005-11-10 Warner-Lambert Company Llc Novel imidazoles
WO2007124734A2 (en) 2006-04-28 2007-11-08 Dieter Mueller-Enoch Compounds a-r-x for the manufacture of pharmaceutical preparations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ping Lu et al., Archives of Biochemistry and Biophysics 1997, 1-7

Similar Documents

Publication Publication Date Title
JP2019516711A5 (en)
JP2018507890A5 (en)
RU2012110007A (en) IMIDAZOCHINOLINS AS DOUBLE LIPIDKINASE AND MTOR INHIBITORS
US20090264443A1 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
JP2011503103A5 (en)
EP2275107A3 (en) Combinations for the treatment of diseases involving cell proliferation
JP2015500887A5 (en)
US20100160351A1 (en) Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
RU2018114518A (en) NEW BICYCLIC COMPOUNDS AS DOUBLE AUTOTAXIN (ATX) / CARBO ACHYDrase (CA) DUAL INHIBITORS
JP2010500962A5 (en)
DE102006019906A1 (en) Use of compounds comprising a hydrophilic tail linked via a hydrocarbon group to a group comprising a carbon or heteroatom free electron pair and/or pi electrons to prepare pharmaceutical compositions
WO2010071865A1 (en) Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20200022960A1 (en) Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
Aghaei et al. Erythropoietin ameliorates the motor and cognitive function impairments in a rat model of hepatic cirrhosis
WO2007019540A3 (en) Controlled release alpha-lipoic acid formulation with an inositol compound
EP0831816A1 (en) Use of benzimidazoles for the manufacture of a medicament for the treatment of leukemia
DE102010012232A1 (en) New imidazole useful in pharmaceutical preparation e.g. for prevention or treatment of cancer diseases, pathological effects of alcohol misuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases
DE102010012235A1 (en) New substituted imidazole compounds, useful e.g. to treat cancer, pathological consequences of alcohol abuse, viral hepatitis, acute and chronic pancreatitis, toxic renal disease and hepatic insulin resistance in diabetes mellitus
DE102010012233A1 (en) New substituted imidazole compounds, useful e.g. to treat cancer, pathological consequences of alcohol abuse, viral hepatitis, acute and chronic pancreatitis, toxic renal disease and hepatic insulin resistance in diabetes mellitus
WO2022079290A3 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
Ezekwesili et al. Toxicity of Acalypha torta (Muell) leaves ethanolic extract in mice and rat
McCubbin et al. Tetrathiomolybdate is effective in a mouse model of arthritis.
WO2018214754A1 (en) Triazole derivative and use thereof in agriculture
JP2015536324A5 (en)
JP2018536637A5 (en)

Legal Events

Date Code Title Description
R120 Application withdrawn or ip right abandoned
R120 Application withdrawn or ip right abandoned

Effective date: 20110902